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PCR amplification of the erm(41) gene can be used to predict the sensitivity 
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A worldwide increase in the Mycobacterium abscessus (M. abscessus) complex has been 
reported. The purpose of this study was to investigate the diversity of the rrl and erm(41) 
genes, both of which are related to macrolide sensitivity in the M. abscessus complex. We 
also examined the efficacy of mass spectrometry as an alternative to molecular testing to 
classify subspecies of the M. abscessus complex. Fourteen strains of the M. abscessus 
complex were obtained, and based on conventional analyses using housekeeping genes, 57% 
were determined to be M. abscessus subsp. abscessus, 43% were M. abscessus subsp. 
massiliense, and none were identified as M. abscessus subsp. bolletii. However, depending on 
the strain, it was not always possible to distinguish between the subspecies by mass 
spectrometry. PCR products for the rrl and erm(41) genes were directly sequenced. Overall, 
7.1% of the strains were found to have a rrl mutation, and 92.9% carried a T at position 28 of 
erm(41). Results presented here suggest that the main cause of treatment failure for M. 
abscessus complex infections is inducible macrolide resistance encoded by the erm(41) gene. 
From a strictly pragmatic standpoint, the phenotypic function of a putative erm(41) gene is 
the most important piece of information needed by clinicians to prescribe an effective 
treatment. Although PCR amplification of erm(41) is not sufficient to differentiate the M. 
abscessus complex subspecies, PCR can be easily and efficiently used to predict the 
sensitivity of members of the M. abscessus complex to clarithromycin. 
 
1. Introduction 
Recent epidemiology research has revealed a worldwide increase in non-tuberculous 
mycobacteria (NTM) infections. In Japan in particular, the Mycobacterium abscessus (M. 
abscessus) complex is the third most common pathogen in pulmonary diseases caused by 
NTM, after the Mycobacterium avium complex and Mycobacterium kansasii (1). The M. 
abscessus complex is categorized as rapidly growing mycobacteria, defined by visible growth 
within seven days, and is one of the most difficult pathogens to treat. Over the past decade, 
the M. abscessus complex has been subclassified into three new subspecies: M. abscessus 
subsp. abscessus, M. abscessus subsp. massiliense and M. abscessus subsp. bolletii (2). 
Macrolides are the key drugs used for treatment of M. abscessus complex infection; however, 
macrolides are not always effective or in some cases they lose effectiveness during the course 
of treatment. Acquired macrolide resistance is associated with point mutations in the rrl gene, 
which encodes 23S rRNA (3). An erythromycin ribosomal methylase, encoded by erm(41) in 
the M. abscessus complex, confers inducible resistance to macrolides (4). The functionality 
of the erm(41) gene differs depending on the subspecies. Most notably, M. abscessus subsp. 
massiliense has been proposed to have an incomplete erm(41) gene, which is associated with 
macrolide sensitivity. In addition, some M. abscessus subsp. abscessus strains have 
substitutions in the erm(41) gene that also lead to macrolide susceptibility. Thus it is 
important to distinguish the three kinds of subspecies and to analyze the sequences of the rrl 
and erm(41) genes. Matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS) has been used for microbial identification in recent years, 
and several researchers have attempted to apply this tool to differentiate the subspecies of the 
M. abscessus complex. However, different diagnostic criteria have been used at different 
institutions and the results of the method are inconsistent (5-10).  
Few studies have investigated the ratio of subspecies of the M. abscessus complex in Japan, 
or examined their macrolide resistance genes. It is likely that regional differences in the ratios 
of the subspecies and the clinical features of such isolates may exist. The purpose of this 
study was to examine the rrl and erm(41) genes present in M. abscessus complex isolates 
obtained at our institutes located in the Tokyo-Yokohama area, and to compare these results 
to the sensitivity of the isolates to the macrolide antibiotic clarithromycin. We also compared 




Samples and Data collection 
Fourteen strains of the M. abscessus complex were obtained from each patient between July 
2016 and April 2018 at Showa University Hospital (Tokyo) or at Showa University 
Fujigaoka Hospital (Yokohama). For reference, one strain of Mycobacterium fortuitum (M. 
fortuitum) was collected during the period. All strains were of sputum origin except for one 
M. abscessus complex isolate from a bronchoscopy. Clinical isolates were cultured in 
mycobacteria growth indicator tubes (MGIT) and in 2% Ogawa solid medium. M. abscessus 
complex and M. fortuitum were distinguished by DNA-DNA hybridization. All clinical data 
were collected from medical records. Official approval for the study was obtained in advance 
from the Ethics Committee for Research at Showa University (approved numbers 371 and 
2016127). Informed consent was waived because of the retrospective nature of the study. 
 
Molecular Testing 
DNA was extracted from mycobacterial clinical isolates using InstaGene matrix (Bio-Rad 
Laboratories, Hercules, CA) and stored at -20 °C. The amount of DNA extracted ranged from 
104 to 452 ng/μl. Primers for nucleic acid amplification were designed as indicated in Table I. 
PCRs were performed to amplify mutation hot spot regions in the housekeeping genes hsp65, 
rpoB and ITS to classify the strains into the three subspecies using a Mycycler ver.10.65 
thermal cycler (Bio-Rad Laboratories, Hercules, CA). The rrl and erm(41) genes were also 
amplified in a similar manner. All PCR assays were carried out in 25-μl volumes containing 
200 ng of template DNA, 0.1 units of Taq DNA polymerase (Roche Diagnostics, Mannheim, 
Germany), 25 pmol of each primer, and 10 nmol of dNTPs. Cycling parameters were 30 sec 
at 95 °C, 30 sec at 60 °C, and 60 sec at 72 °C for 30 cycles. PCR products were separated on 
a 5% polyacrylamide gel or 1.0% agarose gel. The gels were stained with ethidium bromide 
and photographed under UV illumination. The PCR products were purified and were directly 
sequenced using a BigDye terminator kit and ABI Prism 3130 xl (Applied Biosystems, Foster, 
CA). When sequences could not be obtained by direct sequencing, the PCR products were 
ligated into a pGEM T easy vector (Promega, Madison, WI), which was then used to 
transform JM109 cells, as reported previously (11). Multiple clones were selected and 
plasmid DNA was purified from each and sequenced. The reference sequences for each gene 
were obtained from GenBank (accession numbers CU458896.1: M. abscessus subsp. 
abscessus, AP_014547.1: M. abscessus subsp. massiliense.) 
 
Antibiotic susceptibility test 
Minimum inhibitory concentrations (MICs) of amikacin and clarithromycin were determined 
by the broth microdilution method and were interpreted according to the Clinical and 
Laboratory Standards Institute document M24-A2 (12). Briefly, an appropriate volume of the 
culture was transferred into 3 ml of sterilized saline until the turbidity matched that of a 0.5 
McFarland standard. A 10 μl aliquot of the suspension was used to inoculate 11 ml of 
cation-adjusted Mueller-Hinton medium and 100 μl was distributed into each of the 96 well 
panels. The panels were incubated for 72 h at 30 °C, and growth was determined. To test for 
inducible resistance to clarithromycin, the MICs for clarithromycin were also determined 
after 7 and 14 days of incubation.  
 
Mass spectrometry  
Colonies were transferred into microcentrifuge tubes containing 300 μl of sterile deionized 
water, and the tubes were incubated for 30 min at 95°C. Then samples were mixed with 900 
μl of 70% ethanol by vortexing for 1 min. The suspensions were centrifuged at 13,000 rpm 
for 2 min, and the pellets were dried for 5 min at room temperature and resuspended in 20 μl 
of 100% acetonitrile with zirconia beads. The mixtures were vortexed for 1 min. The samples 
were then suspended with 20 μl of 70% formic acid and centrifuged at 13,000 rpm for 2 min. 
Subsequently, 1 μl of the supernatant from each extract was spotted on a target plate. After 
drying, 1 μl of matrix solution (saturated α-cyano-4-hydroxycinnamic acid in 47.5% 
acetonitrile and 2.5% trifluoroacetic acid) was added onto each spot. Mass spectra were 
obtained on a MALDI Biotyper ver 4.0 configured with Micro flex LT/SH with Mycobacteria 
Library ver.5.0 (Bruker Daltonik, Bremen, Germany). Spectra were analyzed by Flex 




The significance in each group was evaluated with Fisher’s exact test or Pearson’s Chi-square 
test, unpaired student’s t-test, and the nonparametric Mann-Whitney test on ranks. P < .05 
was considered significant. All analyses were performed using JMP 13.0 software (SAS 
Institute, Cary, NC). 
 
3. Results 
Determination of Mycobacterium abscessus complex subspecies by sequencing 
housekeeping genes 
The results of sequence analyses of housekeeping genes are shown in Table II. To distinguish 
the three subspecies, hsp65, rpoB and ITS sequences were determined by direct sequencing 
and compared to reference sequences. The sequences of the hsp65 genes from eight strains 
were consistent with the reference sequence from M. abscessus subsp. abscessus, while those 
from six strains were consistent with the hsp65 reference sequence from M. abscessus subsp. 
massiliense, with the exception of one strain (No.9626), which had a change at position 
280T>A. High heterogeneity of rpoB in the M. abscessus complex has been reported (13). 
The rpoB genes from eight strains were identical to the reference gene from M. abscessus 
subsp. abscessus, while a 37C>T change was present in two strains (No.71740, No.9614), 
and two changes (52C>T and 391C>T) were found in another strain (No.8548). Six strains 
had rpoB sequences identical to the reference sequence from M. abscessus subsp. massiliense, 
with the exception of one substitution, 316T>C that was detected in four strains (No.74369, 
No.77944, No.9626, No.9388). No amino acid changes resulted from these nucleotide 
sequence differences. Together, eight strains were identified as M. abscessus subsp. 
abscessus, and six strains as M. abscessus subsp. massiliense, respectively. The results of 
sequence analyses of the ITS region were consistent with these findings. However, a novel 
insertion sequence (180_181GTTGT) was found in one strain of M. abscessus subsp. 
abscessus (No.71740) 
 
Patients and characteristics 
As mentioned above, results were obtained for all patients, 57% (8 of 14) of whom were 
infected with M. abscessus subsp. abscessus, and 43% (6 of 14) of whom were infected with 
M. abscessus subsp. massiliense, respectively. None were infected with M. abscessus subsp. 
bolletii. Table 3 shows the patient characteristics. There were seven males and seven females 
whose ages at diagnosis ranged from 30 to 83 years: thirteen were Japanese and one was 
Indian. According to the guidelines published by the American Thoracic Society/Infectious 
Diseases Society of America (14), all patients were newly diagnosed with M. abscessus 
complex pulmonary disease based on at least two positive culture results derived from 
pulmonary samples. As shown in Table III, there was no significant association of the 
subspecies with age, body-mass index, gender, smoking history, radiological findings, 
hemoptysis, sputum smear, or C-reactive protein.  
 
Gene status of rrl and erm(41) 
Sequence differences identified in the rrl and erm(41) genes are summarized in Table IV. In 
the rrl gene, a A>G change was detected at position 2059 in one strain (No.8006), but no 
other alterations were found. As for the erm(41) gene, nucleotides at positions 64_65 and 
159_432 were deleted in strains of M. abscessus subsp. massiliense, compared to the M. 
abscessus subsp. abscessus strains. Eight substitutions were found in the M. abscessus subsp. 
abscessus isolates, whereas no substitutions were found in the strains of M. abscessus subsp. 
massiliense. In those isolates of M. abscessus subsp. abscessus, 28T>C, 238A>G and 
419C>T substitutions were responsible for the amino-acid changes W10R, I80V and P140L, 
respectively. As shown in Figure 1, the sizes of the PCR products amplified from the erm(41) 
genes were consistent with sequencing results (673 base pairs for M. abscessus subsp. 
abscessus, and 397 base pairs for M. abscessus subsp. massiliense), and identifications based 
on the size of the erm(41) gene were consistent with those based on hsp65, rpoB and ITS 
sequences.  
 
Antimicrobial sensitivity  
Table V shows the antibiotic susceptibility of the M. abscessus strains to amikacin and 
clarithromycin. The MICs of amikacin ranged from 2 to 16 μg/ml, which indicated that all 
strains were sensitive. There was no difference in the MICs between the two subspecies. M. 
abscessus subsp. abscessus isolates were sensitive to clarithromycin on day 3, but the MICs 
were significantly higher on day 14 with one exception (No.9944). In contrast, the strains of 
M. abscessus subsp. massiliense were susceptible to clarithromycin on days 3 through 14, 
except for one strain (No.8006), which showed resistance from the start. Strain No.9626 was 
sensitive early in the testing period, but the MIC was about 4-fold higher on day 14. 
 
MALDI TOF-MS analysis 
The details of mass spectra are shown in Figures 2 and 3. Of the 14 isolates, 11 were 
analyzed by MALDI TOF-MS. For reference, one clinical isolate of M. fortuitum was 
simultaneously analyzed in a similar manner. The 11 strains were identified as M. abscessus 
complex (score range, 1.66 to 2.14) and were correctly differentiated from the strain of M. 
fortuitum (see supplemental figure). As shown in Figure 2, the representative spectra of M. 
abscessus complex subspecies were similar at a laser frequency of 50 Hz across 2,000 to 
12,000 m/z. When magnifying the spectrum (Figure 3), distinctive peaks reported previously 
(8,10) were detected in some cases, but not in all samples. More specifically, peaks around 
4390, 7639, 8781 and 9473 m/z for M. abscessus subsp. abscessus and peaks around 4385, 
7669, and 8767 m/z for M. abscessus subsp. massiliense were found. However, each baseline 
was unstable and the peaks were wide and low for these strains. Moreover, discriminating 
peaks were mostly of low intensity or were overlapping. Thus, detection of clearly 
identifiable differences between strains of different subspecies was extremely difficult. 
Overall, it was possible to discriminate between M. abscessus subsp. abscessus and M. 
abscessus subsp. massiliense by using mass spectra only in some cases.  
 
4. Discussion 
In the current study, M. abscessus complex isolates obtained from patients treated at our 
institutes located in the Tokyo-Yokohama area were analyzed. Overall, 57% (8 of 14) of the 
isolates were identified as M. abscessus subsp. abscessus, 43% (6 of 14) as M. abscessus 
subsp. massiliense, and none as M. abscessus subsp. bolletii. It has been reported that M. 
abscessus subsp. abscessus is the most predominant subspecies of the complex followed by 
M. abscessus subsp. massiliense, and that M. abscessus subsp. bolletii is quite rare, ranging 
from 0 - 3% in Japan (15-19). There were no significant differences in clinical features 
between M. abscessus subsp. abscessus and M. abscessus subsp. massiliense. Clinical 
characteristics of the M. abscessus complex did not help us to distinguish those subspecies, 
which is consistent with findings reported in the literature (15,20). 
  The proportion of the M. abscessus complex subspecies varies depending on the region 
from which they are isolated. Compared to Western Europe, the prevalence of M. abscessus 
subsp. bolletii is lower in East Asian countries (21-24).
 
Although, M. abscessus subsp. 
abscessus is the most predominant subspecies of the complex in most parts of the world, 
some studies have reported that M. abscessus subsp. massiliense is more abundant than M. 
abscessus subsp. abscessus in some parts of East Asia such as Taiwan and Korea (5,21,22,25) 
 
Actually whole-genome sequencing analyses revealed genetic distinctions between M. 
abscessus subsp. abscessus isolates in Asia and Western Europe (26), suggesting that the 
phylogenetic diversity correlates with the regional ratio of the subspecies.  
  The current commercial system for NTM differentiation in Japan consists of the 
DNA-DNA hybridization method, which is unable to differentiate subspecies of the M. 
abscessus complex. The three subspecies also cannot be distinguished by 16S rRNA gene 
sequencing, which is commonly used for bacterial taxonomy in academic research, because 
the 16S rRNA genes in the three subspecies are 100% identical (27,28). The differentiation 
requires sequencing of several housekeeping genes, which is not easy to accomplish in most 
mycobacteriology laboratories. Hence, these three subspecies have not been distinguished in 
hospital laboratories. Sequencing of a single target gene may lead to inaccurate identification 
of closely related subspecies; however, multilocus sequence analyses of the M. abscessus 
complex have been described using hsp65, rpoB, ITS, gyrB, dnaA recA, and secA (29). 
Although some other methods based on technology developed by multilocus sequence 
analyses have been designed, such as variable-number tandem repeat analysis (18,19,30,31) 
and multiplex PCR (17,32), those methods are complicated. In the present study, subspecies 
of the M. abscessus complex were differentiated based on partial sequences of the hsp65 and 
rpoB genes, and results of ITS sequencing were also consistent in differentiating the two 
subspecies. In a subset of M. abscessus complex isolates, a hybrid genetic pattern for the 
hsp65 and rpoB genes has been reported (33,34), presumably the result of horizontal gene 
transfer between the subspecies. In such cases ITS gene analysis was essential to identify the 
subspecies. Sequencing of at least three housekeeping genes should therefore be carried out 
for subspecies identification. 
 
  Numerous institutions are seeking an alternative way to distinguish the M. abscessus 
subspecies in clinical practice. MALDI TOF-MS has been evaluated for the identification of 
microorganisms including mycobacteria. However in this study, it was not possible to 
distinguish between the M. abscessus subspecies of all isolates by MALDI TOF-MS. 
Although several institutes have reported the efficacy of MALDI TOF-MS in differentiating 
the three subspecies of the M. abscessus complex (5-10), methods for sample preparation and 
analysis, and diagnostic criteria have not been standardized. When defining the range from 
2,000 to 20,000 m/z, ribosomal protein accounts for 50 to 70% of the peptide detected by 
MALDI TOF-MS. Thus, it is easy to distinguish between species that contain diverse 
ribosomal proteins. In fact, the current study revealed obvious differences between M. 
fortuitum and the M. abscessus complex by mass spectra (see supplemental figure). However, 
the mass spectrometry peaks may be affected by variations in culture media formulations, 
duration of growth, and other conditions. The utility of MGIT liquid medium (10), 5% sheep 
blood agar (6), Middlebrook 7H11
 
(7)  and Lowenstein-Jensen agar (9) have been reported 
for MALDI TOF-MS. In our study, colonies derived from 2% Ogawa solid medium were 
prepared. Thus, the diagnostic criteria for MALDI-TOF analysis differ depending on the 
laboratory carrying out the analyses. Since there are few differences in the ribosomal proteins 
between the M. abscessus complex subspecies, and the sample preparation for mass spectra is 
even affected by climate, the procedure is often poorly reproducible. Considerable effort 
would be necessary to optimize and standardize a protocol to obtain reproducible mass 
spectrometry results for differentiating the M. abscessus complex subspecies.  
 
  rrl mutations confer acquired resistance and nucleotide T28 of erm(41) is associated with 
inducible resistance. Since most of the alterations identified in this study were in the erm(41) 
gene (92.9%; 13 of 14 isolates) rather than the rrl gene (7.1%;1 of 14), we concluded that the 
main cause of treatment failure for M. abscessus complex infections was inducible resistance 
encoded by the erm(41) gene. One strain of M. abscessus subsp. massiliense (No.8006) 
harboring a point mutation 2059A>G in the rrl gene showed resistance to clarithromycin 
from day 3 through day 14 (MIC > 128 μg/ml). The presence of rrl mutations was reported in 
up to 30% of newly isolated strains in East Asia (16,35), whereas no rrl mutations were 
identified at the time of diagnosis in Spain (36). It has been reported that mutations in the rrl 
gene rapidly accumulate following clarithromycin use in monotherapy (3). Conversely, 
several studies have reported acquired resistance due to rrl mutations in the absence of any 
macrolide exposure (16,37). However, an in vitro study reported that rrl mutations at position 
2058 or 2059 were observed during incubation with clarithromycin (38). In East Asia, low 
dose macrolides are often administered for prolonged periods to treat chronic respiratory 
disorders, such as diffuse panbronchiolitis, to stimulate an immunomodulatory effect (39). 
Hence, careful attention is needed when prescribing macrolides to patients initially diagnosed 
with pulmonary disease caused by M. abscessus complex. One strain of M. abscessus subsp. 
abscessus (No.9944) carried a substitution at position 28T>C in the erm(41) gene, which 
resulted in an amino acid change (W10R), and showed a low MIC value for clarithromycin. 
Other strains that harbored amino acid substitutions 238A>G (I80V) or 419C>T (P140L) 
showed inducible resistance. These data are in agreement with previous reports (4,37,40) 
suggesting that the 5' end of the erm(41) gene is a key region because this region is also 
predicted to carry a second open reading frame encoding a leader peptide that regulates 
expression of the erm(41) gene itself (4). In fact, two base deletions (61_62del) were 
commonly detected in M. abscessus subsp. massiliense, and in addition, strains harboring a 
C>T substitution at position 19 that led to a stop codon (R7stop) were identified in a case 
report of M. abscessus subsp. abscessus (40). With rare exceptions such as the presence of a 
full-length erm(41) gene (41,42), M. abscessus subsp. massiliense is generally not associated 
with inducible macrolide resistance because most strains harbor a truncated erm(41) gene 
(4,21,43). Interestingly, in the present study, one strain (No.9626) showed a low initial MIC 
but the MIC increased 4-fold by 14 days. This observation suggests that mechanisms not 
involving erm(41) can cause inducible resistance. No strains that simultaneously harbored 
both a rrl mutation and nucleotide T28 in erm(41) were detected in this study; however, 
numerous studies have revealed that both resistance mechanisms can occur concurrently 
(36,38), and that a functional erm(41) gene does not exclude selection for rrl mutations (44).  
  As described above, the two subspecies of the M. abscessus complex were found, which is 
consistent with the results of other studies showing the predominance of M. abscessus subsp. 
abscessus and M. abscessus subsp. massiliense in East Asia (15,16,21,24). Data from the 
current study indicate that the principal difference between the two subspecies was the size of 
the erm(41) gene. Several studies have revealed the presence of a complete erm(41) gene in 
M. abscessus subsp. massiliense strains (41,42) and a truncated erm(41) gene in M. abscessus 
subsp. bolletii (36), suggesting that M. abscessus subsp. massiliense acquired a full-length 
erm(41) gene by horizontal transfer from M. abscessus subsp. abscessus or M. abscessus 
subsp. bolletii, and that a truncated erm(41) gene was transferred from M. abscessus subsp. 
massiliense to M. abscessus subsp. bolletii. Additionally, a change at position 28T>C has 
been reported in M. abscessus subsp. bolletii (21). Therefore, although horizontal gene 
transfer between subspecies is probably quite rare, erm(41) PCR is not proposed as the best 
way to differentiate M. abscessus complex subspecies. However, erm(41) PCR can be easily 
and efficiently used for the prediction of sensitivity to clarithromycin in the M. abscessus 
complex. The phenotypic function of a putative erm(41) gene is important for the clinician 
from a strictly pragmatic standpoint. Likewise, M. abscessus complex subspecies should be 
categorized based on the presence of a functional erm(41) gene and macrolide sensitivity 
especially if horizontal gene transfer increases in the future.  
  In conclusion, the present study demonstrates the features of M. abscessus subsp. 
abscessus and M. abscessus subsp. massiliense, isolated in the Tokyo-Yokohama area. No 
strains of M. abscessus subsp. bolletii were detected. The two subspecies were quite similar 
to each other in clinical characteristics and on the basis of mass spectrometry analysis; 
however, it is possible to predict clarithromycin susceptibility in strains of the two species by 
PCR amplification of the erm(41) gene. This is a simple and useful method that can be 
carried out routinely in hospital laboratories, and is recommended to predict inducible 
resistance to macrolides before determining the MICs, which requires 14 days of incubation 
for M. abscessus complex subspecies.   
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Figure Legends:  
Figure 1: Representative PCR products for the erm(41) gene. The amplified products from 
Mycobacterium abscessus subsp. abscessus strains (No.9016, No.8377, No.9944, No. 
9854) were 673 bp in length, whereas those from Mycobacterium abscessus subsp. 
massiliense strains (No.9835, No.9626) were 397 bp in length.  Far left lane, DNA 
size standard; Lane 1, No.8377; Lane 2, 9016; Lane 3, 9626; Lane 4, 9944; Lane 5, 
9835; Lane 6, 9854.  
 
Figure 2: Representative MALDI-TOF spectra of Mycobacterium abscessus subsp. abscessus 
and Mycobacterium abscessus subsp. massiliense (2,000~12,000 m/z). 
 
Figure 3: Eight peaks differentiate the two Mycobacterium abscessus complex subspecies. 
Diagram shows the relative intensity (%) against the mass-to-charge ratio values of the 
discriminating peak regions of MALDI-TOF averaged mass spectral profiles for each 
subspecies.  
 
Figure S1: MALDI-TOF gel views for Mycobacterium fortuitum, Mycobacterium abscessus 
subsp. abscessus and Mycobacterium abscessus subsp. massiliense (4,000~12,000 
m/z). 
Table I  Primer design.   
    
Target Primers Sequence bp 
hsp65 hsp65F 5'-ACCAACGATGGTGTGTCCAT-3' 441 
 hsp65R 5'-CTTGTCGAACCGCATACCCT-3'  
rpoB rpoBF 5'-GAGGGTCAGACCACGATGAC-3' 408 
 rpoBR 5'-AGCCGATCAGACCGATGTT-3'  
ITS ITSF 5'-TTGTACACACCGCCCGTC-3' 490 
 ITS336R 5'-CTTCTAGTGCCAAGGCATTCACC-3'  
rrl rrl2145F 5'-GCGAAATTCCTTGTCGGGTAAGT-3' 283 
 rrl2427R 5'-GGATATACGGTCCGAGGTTAG-3'  
erm(41) erm-86F 5'-GACCGGGGCCTTCTTCGTGAT-3' 673 
 erm64R 5'-GACTTCCCCGCACCGATTCC-3'  
bp: base pair.       
 
Table II   Sequence differences in clinical isolates of the M. abscessus complex.                 
                               
Strain number  hsp65a      rpoBb               ITSc      
  115 118 127 190 280 340  10 31 37 52 88 124 127 136 202 277 316 343 376 379 391  25 60 98 180 276 insertion 
CU458896 d   T T C C T C   T T C C T G C T C C T C C C C   T A - C G   
                               
9016  T T C C T C  T T C C T G C T C C T C C C C  T A - C G  
8377  T T C C T C  T T C C T G C T C C T C C C C  T A - C G  
9944  T T C C T C  T T C C T G C T C C T C C C C  T A - C G  
71740  T T C C T C  T T T C T G C T C C T C C C C  T A - T G c.180_181insGTTGT 
9614  T T C C T C  T T T C T G C T C C T C C C C  T A - C G  
9854  T T C C T C  T T C C T G C T C C T C C C C  T A - C G  
8548  T T C C T C  T T C T T G C T C C T C C C T  T A - C G  
9419  T T C C T C  T T C C T G C T C C T C C C C  T A - C G  
74369  G C T T T T  C C C C C A T C G T C T T T C  C G C T A  
9835  G C T T T T  C C C C C A T C G T T T T T C  T G C C A  
77944  G C T T T T  C C C C C A T C G T C T T T C  C G C T A  
9626  G C T T A T  C C C C C A T C G T C T T T C  T G C C A  
9388  G C T T T T  C C C C C A T C G T C T T T C  C G C T A  
8006  G C T T T T  C C C C C A T C G T T T T T C  T G C C A  
                               
AP014547 e   G C T T T T   C C C C C A T C G T T T T T C   T G C C A   
M. abscessus complex: Mycobacterium abscessus complex. Ins: insertion.                
a Nucleotide positions are based on the M. abscessus subsp. massiliense sequence (accession no. AB548601).            
b Nucleotide positions are based on the M. abscessus subsp. massiliense sequence (accession no. AB548600).            
c Nucleotide positions are based on the  M. abscessus subsp. massiliense sequence (accession no. AB548603).            
d CU458896 (ATCC19977) is a reference sequence for M. abscessus subsp. abscessus.                
e AP014547 (JCM15300) is a reference sequence for M. abscessus subsp. massiliense.                
                               
                               
Table Ⅲ  Characteristics of study participants . 
  M. abscessus 
subsp. abscessus 




    (n=8)   (n=6)     
Age  69.1 ± 18.1  62.5 ± 9.7  0.435 
BMI, kg/m2  19.6 ± 3.4  18.6 ± 1.8  0.552 
Gender       
   Male  3 (21.4)  4 (28.5)  0.592 
   Female  5 (35.7)  2 (14.2)   
Smoking       
   Never  6 (42.8)  2 (14.2)  0.277 
   Ever  2 (14.2)  4 (28.5)   
Radiological findings     
   Cavity  1 (7.1)  2 (14.2)  0.538 
Sympton of hemoptysis     
  Yes  2 (14.2)  3 (21.4)  0.58 
  No  6 (42.8)  3 (21.4)   
Positive smear       
   Yes  6 (42.8)  3 (21.4)  0.58 
   No  2 (14.2)  3 (21.4)   
Laboratory findings     
 CRP, mg/dl   0.96 ± 1.22   1.68 ± 2.17   0.492 
Date are expressed as numbers (%), values are means ± standard deviation. 
M. abscessus subsp. abscessus: Mycobacterium asbcessus subspecies 
abscessus. M. abscessus subsp. massiliense: Mycobacterium abscessus 
subspecies massiliense, BMI: Body Mass Index, CRP: C-reactive protein. 
 
Table Ⅳ   Sequence differences in the rrl and erm(41) genes from clinical isolates of the M. abscessus complex.          
                             
  rrla   erm(41)b                       
    2058 2059   -28 -4 28 41 46 64 65 85 90 109 120 123 159 238 255 279 330 336 419 438 466 amino acid change   
CU458896 c  A A  A C T C A C G G C G A A T A G G A T C A G    
                             
9016  A A  A C T C A C G G C G A A C G** G G C T C A G  I80V**  
8377  A A  A C T C A C G G C G A A T A G G A T C A G    
9944  A A  A C C* C A C G G C G A A C G** G G C T C A G W10R* I80V**  
71740  A A  A C T C A C G G C G A A C G** A T C C C A G  I80V**  
9614  A A  A C T C A C G G C G G A C G** A T C C C A G  I80V**  
9854  A A  A C T C A C G G C G A A T A G G A T C A G    
8548  A A  A C T C A C G G C G A A C G** A T C C T*** A G  I80V** P140L*** 
9419  A A  A C T C A G G G C G A A C G** A T C C C A G  I80V**  
74369  A A  G T T A G - - T T A A G - - - - - - - C A    
9835  A A  G T T A G - - T T A A G - - - - - - - C A    
77944  A A  G T T A G - - T T A A G - - - - - - - C A    
9626  A A  G T T A G - - T T A A G - - - - - - - C A    
9388  A A  G T T A G - - T T A A G - - - - - - - C A    
8006  A G  G T T A G - - T T A A G - - - - - - - C A    
                             
AP014547 d   A A   G T T A G - - T T A A G - - - - - - - C A       
M. abscessus complex: Mycobacterium abscessus complex.              
a Numbering system for the rrl gene from Escherichia coli.                    
b Numbering system for the erm(41) gene, with the GTG start codon as 1.                  
c CU458896 (ATCC19977) is a reference sequence for M. abscessus subsp. abscessus.               
d AP014547 (JCM15300) is a reference sequence for M. abscessus subsp. massiliense.               
* T to C transition at position 28 (28T>C) leading to a Trp>Arg amino acid change at codon 10. 
        
    
** A to G transition at position 238 (238A>G) leading to a Ile>Val amino acid change at codon 80. 
   
    
*** C to T transition at position 419 (419C>T) leading to a Pro>Leu amino acid change at codon 140.       
 
Table V Antibiotic susceptibilities of M. abscessus complex isolates based on MIC (μg/mL) values. 
       
  Amikacin Clarithromycin   
  strains no. day 3 day 3 day 7 day 14  
M. abscessus subsp. abscessus 9016 16 0.125 64 64  
 8377 16 0.5 64 >128  
 9944 8 ≤0.06 ≤0.06 ≤0.06  
 71740 8 0.25 32 32  
 9614 8 0.25 64 64  
 9854 8 0.125 >128 >128  
 8548 8 ≤0.06 64 >128  
 9419 8 0.5 32 32  
M. abscessus subsp. massiliense 74369 16 0.25 0.25 0.25  
 9835 16 ≤0.06 ≤0.06 ≤0.06  
 77944 4 ≤0.06 ≤0.06 ≤0.06  
 9626 16 0.125 0.25 0.5  
 9388 8 ≤0.06 ≤0.06 ≤0.06  
 8006 2 >128 >128 >128  
MIC: minimum inhibitory concentration. M. abscessus subsp. abscessus: Mycobacterium 
abscessus subspecies abscessus. M. abscessus subsp. massiliense: Mycobacterium abscessus 
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